Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.

After finishing at $5.19 in the prior trading day, Vir Biotechnology Inc (NASDAQ: VIR) closed at $5.24, up 0.96%. In other words, the price has increased by $0.96 from its previous closing price. On the day, 0.74 million shares were traded. VIR stock price reached its highest trading level at $5.25 during the session, while it also had its lowest trading level at $5.04.

Ratios:

Our goal is to gain a better understanding of VIR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.01 and its Current Ratio is at 7.01. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Evercore ISI on September 03, 2025, initiated with a Outperform rating and assigned the stock a target price of $12.

On August 27, 2025, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $14. JP Morgan Downgraded its Overweight to Neutral on January 29, 2024, whereas the target price for the stock was revised from $23 to $9.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 02 ’25 when SATO VICKI L sold 22,000 shares for $4.99 per share. The transaction valued at 109,811 led to the insider holds 1,254,391 shares of the business.

SATO VICKI L sold 22,000 shares of VIR for $109,699 on Aug 01 ’25. The Director now owns 1,276,391 shares after completing the transaction at $4.99 per share. On Jul 15 ’25, another insider, Eisner Mark, who serves as the EVP and Chief Medical Officer of the company, sold 6,796 shares for $5.47 each. As a result, the insider received 37,162 and left with 108,204 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIR now has a Market Capitalization of 727919808 and an Enterprise Value of 224133072. For the stock, the TTM Price-to-Sale (P/S) ratio is 38.31 while its Price-to-Book (P/B) ratio in mrq is 0.77. Its current Enterprise Value per Revenue stands at 11.796 whereas that against EBITDA is -0.404.

Stock Price History:

The Beta on a monthly basis for VIR is 1.24, which has changed by -0.33077908 over the last 52 weeks, in comparison to a change of 0.1725707 over the same period for the S&P500. Over the past 52 weeks, VIR has reached a high of $14.45, while it has fallen to a 52-week low of $4.16. The 50-Day Moving Average of the stock is 2.99%, while the 200-Day Moving Average is calculated to be -21.58%.

Shares Statistics:

The stock has traded on average 1.29M shares per day over the past 3-months and 2088210 shares per day over the last 10 days, according to various share statistics. A total of 138.89M shares are outstanding, with a floating share count of 89.59M. Insiders hold about 35.51% of the company’s shares, while institutions hold 57.18% stake in the company. Shares short for VIR as of 1755216000 were 11487884 with a Short Ratio of 8.94, compared to 1752537600 on 11294318. Therefore, it implies a Short% of Shares Outstanding of 11487884 and a Short% of Float of 13.33.

Earnings Estimates

The current rating of Vir Biotechnology Inc (VIR) reflects the combined expertise of 7.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.71, with high estimates of -$0.59 and low estimates of -$0.85.

Analysts are recommending an EPS of between -$2.87 and -$3.84 for the fiscal current year, implying an average EPS of -$3.26. EPS for the following year is -$2.88, with 8.0 analysts recommending between -$2.4 and -$3.54.

Revenue Estimates

For the next quarter, 7 analysts are estimating revenue of $2.05M. There is a high estimate of $3.9M for the next quarter, whereas the lowest estimate is $500k. A total of 9 analysts have provided revenue estimates for VIR’s current fiscal year. The highest revenue estimate was $37M, while the lowest revenue estimate was $4.7M, resulting in an average revenue estimate of $11.47M. In the same quarter a year ago, actual revenue was $74.2MBased on 9 analysts’ estimates, the company’s revenue will be $13.22M in the next fiscal year. The high estimate is $29.65M and the low estimate is $3M.